Gilead Sciences, Inc.GILD

Healthcare
Neutral

ASignal's systematic analysis rates GILD as Neutral. Gilead Sciences, Inc. has a market cap of $166.72B, a P/E of 18.55, a 31.0% net margin, and 4.4% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 18, 2026

The case on GILD

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Positive MACD histogram indicating strengthening momentum
  • Price above 20-day and 50-day moving averages
  • Strong free cash flow of $7.93B
  • High return on equity (43.36%)
  • Operating margin of 39.28% indicates pricing power
  • Forward P/E of 13.83x below current P/E, suggesting earnings growth expectations
VS
Bear case
  • Revenue growth at 4.40% is relatively low
  • High PEG ratio of 2.14x suggests overvaluation relative to growth
  • Debt-to-equity ratio of 0.95x approaching high levels
  • Only 1 Reddit mention, indicating low retail investor interest

Key facts

Sector
Healthcare
Market cap
$166.72B
P/E ratio
18.55
Gross margin
79.4%
Net margin
31.0%
Rev growth YoY
4.4%
Price (Jul 18, 2026)
$134.28

Peers

Clustered with GILD by analysis-profile similarity.

Subscriber-only

See the full verdict on GILD

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes GILD

Most investors never get a second opinion, let alone several. ASignal runs GILD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Gilead Sciences, Inc. (GILD) Stock Analysis - ASignal rates it Neutral